SBIR Phase I: A Portable Oxygen Concentrator with High Flow Rates for In-home Therapy (COVID-19)

SBIR 第一阶段：用于家庭治疗的高流量便携式制氧机 (COVID-19)

• 批准号: 2136709
• 负责人: Jun Kamata
• 金额: $ 25.6万
• 依托单位: AIROMATIX INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-15 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136709&HistoricalAwards=false
• 关键词: SBIR; Phase; Portable; Oxygen; Concentrator

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to enable easy oxygen delivery to patients with respiratory conditions. Currently, patients requiring high flow-rates of oxygen above 4 L/min require oxygen tanks that are large, heavy and can be hazardous, limiting mobility and transportation options. The proposed system produces breathable oxygen at higher flow rates and lower energy compared to current portable oxygen concentrators, enabling sustained patient use. This enables sustained oxygen production in a portable manner to manage medical conditions causing oxygen deprivation, including Chronic Obstructive Pulmonary Disease (COPD) and Coronavirus Disease (COVID-19). This Small Business Innovation Research (SBIR) Phase I project will develop a portable system that utilizes a novel photocatalytic (light activated) reaction to separate oxygen from ambient air, trapped in a chemical solution, then released as needed through a temperature-controlled reaction. This project will monitor the capture and release reactions using absorption spectroscopy to determine the ideal conditions of oxygen production. Several photosensitizer chemical compounds (fullerene C70 and C60, rubrene, and methylene blue with urea) will be evaluated on system longevity by continuously cycling the systems under higher temperatures and light exposure, and monitoring their effects on oxygen production. A prototype will then be developed that generates targeted oxygen flow rates at the desired rate of energy consumption, and the oxygen produced validated as safe for inhalation using bench tests.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛的影响/商业潜力是，可以轻松地向患有呼吸系统疾病的患者递送氧气。 当前，需要高于4 l/min的氧气流量的患者需要大，重，并且可能是危险的，可以限制迁移率和运输选择。与当前的便携式氧气浓度器相比，所提出的系统在较高的流速和较低的能量下产生透气氧，从而可以持续使用患者。这使持续的氧气产生以便携式方式管理导致氧气剥夺的医疗状况，包括慢性阻塞性肺疾病（COPD）和冠状病毒病（COVID-19）。这项小型企业创新研究（SBIR）I期项目将开发一种便携式系统，该系统利用一种新型的光催化（光激活）反应将氧与环境空气分离，被困在化学溶液中，然后根据需要通过温度控制的反应释放。该项目将使用吸收光谱法监测捕获和释放反应，以确定氧气产生的理想条件。通过连续循环在较高的温度和光暴露下，将评估几种光敏化合物（富勒烯C70和C60，rubrene和甲基蓝），并用尿素进行尿素的甲基蓝色），并监测其对氧气产生的影响。然后将开发一个原型，该原型以所需的能耗生成靶向的氧气流量，并使用基准测试被验证的氧气被验证为安全的氧气。这项奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子优点和更广泛影响的审查审查的评估来通过评估来支持的。